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INTRODUCTION
Atopic dermatitis (AD) is caused by a dysregulated immune re-
sponse and skin barrier disruption (1-4). AD patients generally
have elevated IgE as well as enhanced differentiation of Th1, Th2,
and Th17 cells (2, 5). Moreover, increased numbers of Th17 cells
are associated with AD severity (6). As for skin barrier disruptions,
loss-of - function mutations of filaggrin are associated with AD
(7, 8) and filaggrin-deficient mice develop skin inflammation that
is accompanied by increased Th17 differentiation (3, 9). Therefore,
depending on disease severity, AD treatment can involve a combi-
nation of oral anti -histamines, anti - leukotrienes and ointments
that include steroids, FK506 or NSAIDs (1). However, the long-
term use of steroids or FK506 may cause severe side effects, which
is problematic for younger patients in particular.
Several studies have shown that ω3 free fatty acid (FFA) intake
through supplementation or foods can suppress the progression
of inflammatory diseases (10, 11). These FFAs could suppress
inflammatory responses by inhibiting production of IL-6 as well
as prostaglandins and leukotrienes (12) that participate in skin in-
flammation by activating T cells and neutrophils (13). Moreover,
the application of the leukotriene B4 (LTB4) receptor antagonist
ONO-4057 inhibited spontaneous itch phenotypes in NC mice that
are an animal model of AD (14). This finding suggests that LTB4
plays an important role in AD progression.
We developed an ointment containing the FFAs docosahex-
aenoic acid (DHA) and eicosapentaenoic acid (EPA) as a topical AD
therapeutic and tested its efficacy in suppressing symptoms in AD
patients (15). To determine the molecular mechanism by which
this ointment alleviates symptoms, we evaluated the therapeutic
efficacy of DHA/EPA on AD-like disease in NC/Nga mice. We
found that DHA/EPA administered together with FK506 can ame-
liorate AD by suppressing LTB4 production. These data demon-
strate the molecular basis for the therapeutic efficacy of DHA/EPA
on AD and suggest that DHA/EPA may be a useful component in
ointments used to treat AD.
MATERIAL AND METHODS
Mice
NC/Nga mice (8-10 weeks old) were purchased from Charles
River (Yokohama, Japan) and housed in the Animal Research Cen-
ter of the University of Tokushima under specific pathogen-free
conditions. All mice were housed under specific pathogen-free
conditions. The animal studies in this manuscript was approved by
the Committee on the Ethics of Animal Experiments of Tokushima
University and the care and use of animals complied with institu-
tional guidelines. All surgery was performed under sodium pento-
barbital anesthesia, and all efforts were made to minimize suffering.
DHA/EPA
Cod liver oil containing DHA 20% and EPA 10% were provided by
NOF Corporation (Tokyo, Japan).
Dermatitis model
The hair in the rostral region on the backs of the mice was re-
moved with a depilatory cream. The mice were then challenged
with an ointment that included a Dermatophagoides farinae body
extract (Biosta AD) (Biostir, Kobe, Japan) twice weekly for 3 weeks.
The first day for the challenge was designated as day 0. Before the
first challenge, the skin barrier was disrupted by treatment with
a 4% SDS solution. The FK506 (0.3 mg) and/or DHA/EPA (Cod
liver oil : 100 mg, EPA 8.3%, DHA 14.6%) ointment was applied at
the area where Biosta AD was painted on days 4, 8, 12, 16,and 20.
ORIGINAL
Treatment with DHA/EPA ameliorates atopic dermatitis-like
skin disease by blocking LTB4 production
Shinya Yoshida1, Koji Yasutomo1, and Toshiyuki Watanabe2
1Department of Immunology & Parasitology, Graduate School of Medicine, Tokushima University, Tokushima 770-8503, Japan, 2Department
of Pediatrics, Takamatsu City Hospital, Takamatsu, Kagawa 760-8351, Japan
Abstract : Atopic dermatitis (AD) is caused by both dysregulated immune responses and an impaired skin barrier.
Although leukotriene B4 (LTB4) is involved in tissue inflammation that occurs in several disorders, including
AD, therapeutic strategies based on LTB4 inhibition have not been explored. Here we demonstrate that progres-
sion of an AD-like skin disease in NC/Nga mice is inhibited when docosahexaenoic acid (DHA)/eicosapentaenoic
acid (EPA) is administered together with FK506. Treatment with DHA/EPA and FK506 decreases the clinical
score of dermatitis in NC/Nga mice and lowers local LTB4 concentrations. The treatment also suppressed the
infiltration of T cells, B cells, eosinophils and neutrophils, and promoted reduced serum IgE levels. Secretion of
IL-13 and IL-17A in CD4+ T cells was lower in DHA/EPA- and FK506-treated mice than in mice treated with FK506
alone. The inhibition of disease progression induced by DHA/EPA was reversed by local injection of LTB4, sug-
gesting that the therapeutic effect of DHA/EPA is LTB4-dependent. Our results demonstrate that treatment of
ADwith DHA/EPA is effective for allergic skin inflammation and acts by suppressing LTB4 production. J. Med.
Invest. 63 : 187-191, August, 2016
Keywords : docosahexaenoic acid, eicosapentaenoic acid, atopic dermatitis, leukotriene B4
Received for publication January 8, 2016 ; accepted February 25, 2016.
Address correspondence and reprint requests to Toshiyuki Watanabe,
M.D., Ph.D. Department of Pediatrics, Takamatsu City Hospital, Takamatsu
760-8351, Kagawa, Japan, and Koji Yasutomo, M.D., Ph.D. Department
of Immunology & Parasitology, Graduate School of Medicine, Tokushima
University, 3 -18 -15 Kuramoto, Tokushima 770-8503, Japan and Fax : +81-
88 -633-7114.
The Journal of Medical Investigation Vol. 63 2016
187
**
erocs lacinil
C
a b
Biosta-untreated Biosta + DHA/EPA
Biosta + FK506 + DHA/EPABiosta + FK506
0
2
4
6
8
10
12
14
Biosta
alone
Biosta +
DHA/EPA
Biosta +
FK506
Biosta +
FK506 +
DHA/EPA
Purification of cells from skin tissue and flow cytometry analysis
Skin tissue was digested with 2.5 mg/mL dispase II (Roche),
3 mg/ml collagenase (Worthington Biochemicals, USA) and 5 μg
DNase (Roche) for 120 min at 37. After removal of cell debris,
cells were stained with APC-conjugated anti -CD3, FITC-conju-
gated anti -B220, PE-Cy7-conjugated Gr1, APC-Cy7-conjugated
CD11b, or PE-conjugated Siglec-F antibody. Flow cytometry was
performed on a FCAS CantoII flow cytometer (Becton Dickinson,
Mountain View, CA).
Cell culture
CD4+ T cells were isolated from lymph nodes by incubating cells
with anti -B220, anti -CD32/16, anti -CD11b, and anti -CD8 mAbs
followed by incubation with anti -rat IgG-coated Dynabeads (Thermo
Fisher Scientific Inc., USA). Purified CD4+ T cells were stimulated
with irradiated spleen cells in the presence of anti -CD3 mAb
(1μg/ml) for 2 days.
Measurement of leukotriene levels
A section of skin (2 cm in diameter) was removed, minced with
scissors and placed in ethanol containing indomethacin and zileu-
ton. After sample homogenization and subsequent centrifugation
for 5 min at 600g and 4, the supernatant was mixed with water
and applied to a C18 Sep-Pak cartridge (Waters, Milford, MA,
USA) equilibrated with methanol. After washing the cartridge with
hexane and then water, lipids were eluted with ethanol. The etha-
nol was evaporated, with the remaining residue suspended in an
enzyme immunoassay buffer included with a LTB4 ELISA assay
kit (Cayman Chemical, Ann Arbor, MI, USA). The protein concen-
tration was measured and the amount of LTB4 was normalized
relative to that of the overall protein.
ELISA
IL-13, IFN-γ, IL-17A, and IL-22 levels in culture supernatants
were measured using an ELISA kit (R&D Systems, Minneapolis,
MN). Serum from mice or standard IgG1, IgM, IgG2b or IgE
(Southern Biotech, AL, USA) were serially diluted with PBS to
coat a 96 well plate overnight at 4. After washing with PBS/0.1%
Tween 20, alkaline phosphatase-conjugated goat anti -mouse IgG1,
IgM, IgG2b, or IgE (Southern Biotech, AL, USA) were added and
incubated at room temperature for 2 hours. After washing wells
with PBS/0.1% Tween 20, alkaline phosphatase activity was deter-
mined using 4-nitrophenyl phosphate disodium salt hexahydrate
(Sigma-Aldrich, MO, USA) as the substrate.
Scoring of skin lesions
The extent of (1) erythema/hemorrhage, (2) scarring/dryness,
(3) edema, and (4) excoriation/erosion was scored as 0 (none), 1
(mild), 2 (moderate), and 3 (severe). The total skin score was
defined as the sum of the individual scoresSD.
Histology
Skin tissue samples were fixed in 10% formalin, embedded in
paraffin, and sectioned. Tissue sections were stained with hema-
toxylin and eosin.
Statistical analysis
The distributed data from interval scales were analyzed with Stu-
dent’s t - test ; a p value of less than 0.05 was considered statistically
significant.
RESULTS
DHA/EPA attenuate atopic dermatitis- like diseases
We sought to analyze the effect of DHA/EPA on atopic-derma-
titis like diseases (AD) in NC/Nga mice, an animal model of AD.
AD is induced in these mice by painting an ointment containing
Dermatophagoides farinae body extract on their backs. We applied
DHA/EPA or FK506 alone or DHA/EPA with FK506 to treat the
AD. Treatment with DHA alone did not ameliorate AD as evaluated
by clinical score and histology (Fig. 1a and b). Meanwhile, treat-
ment with FK506 ameliorated AD symptoms, and treatment with
both FK506 and DHA/EPA further improved the clinical scores
and histology (Fig. 1a and b). These data demonstrate that DHA/
Figure 1. DHA/EPA attenuates skin inflammation
AD was induced by painting an ointment that contained Dermatophagoides farinae body extract onto the dorsal skin of NC/Nga mice. We applied
DHA/EPA or FK506 or DHA/EPA with FK506 on the dorsal skin and evaluated the (a) clinical score and (b) skin histology by HE staining 30 days
after initial induction. The data are shown as meanS.D. (n=8 in each experiment). **indicates statistical difference (p0.01).The data are
representative of six independent experiments.
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EPA can suppress AD when used with FK506.
DHA/EPA decreased the number of T cells that infiltrate the skin
We next evaluated the number of immune-related cells infiltrat-
ing the skin after treatment. Twenty days after initial AD induction,
skin tissue samples were taken and digested with collagenase and
dispase. The number of T cells (CD3+), B cells (IgM+B220+), neu-
trophils (CD11b+Gr1+), and eosinophils (CD11b+SiglecF+) in these
tissue samples were counted (Fig. 2). Treatment with FK506 did
not affect cell numbers of any types of cells. In contrast, treatment
with FK506 and DHA/EPA decreased the number of T cells, neu-
trophils and eosinophils (Fig. 2). These data show that DHA/EPA
treatment could decrease the infiltration of T cells, neutrophils,
and eosinophils in the skin.
DHA/EPA treatment decreases serum IgE and production of IL-
13 and IL-17A by CD4+ T cells
Given that DHA/EPA affects T cell numbers, we assessed serum
immunoglobulin levels after DHA/EPA treatment (Fig. 3a). DHA/
EPA together with FK506 decreased the amount of IgE but not
levels of IgM,IgG1, and IgG2b. We also compared cytokine secre-
tion from CD4+ T cells in mice treated with FK506 alone and FK506
plus DHA/EPA. The CD4+ T cells were purified from fluid drained
from lymph nodes and stimulated with anti -CD3 mAb for 2 days.
IL-13, IL-22, IL-17A, and IFN-γ expression was upregulated by
treatment with Dermatophagoides farinae body extract (Fig. 3b).
Treatment with FK506 and DHA/EPA decreased IL-13 and IL-17A
secretion while FK506 alone did not affect the levels of any of the
cytokines tested. Together these results indicated that DHA/EPA
treatment decreases the secretion of IL-13 and IL-17A from CD4+
T cells.
DHA/EPA treatment decreases LTB4 production
DHA/EPA have the capacity to suppress leukotriene production
(16). We evaluated levels of the leukotriene LTB4 in the skin after
DHA/EPA treatment. Dorsal skin tissue samples were digested
and levels of the LTB4 protein were evaluated. FK506 treatment
did not affect the amount of LTB4 in the skin, while FK506 with
DHA/EPA significantly decreased LTB4 levels (Fig. 4a), indicat-
ing that DHA treatment affects LTB4 production.
To evaluate whether inhibition of LTB4 production contributes
to the suppression of AD by DHA/EPA, we injected LTB4 into the
skin of DHA/EPA-treated mice. LTB4 injection inhibited the effect
of DHA/EPA ointment therapy (Fig. 4b), suggesting that DHA/
EPA-mediated suppression of AD is attributable to the suppres-
sion of LTB4 production.
DISCUSSION
Bioactive lipids such as leukotrienes, prostaglandin, and eicosa-
noids are generated from arachidonic acid by 5- lipoxygenase and
cyclooxygenase (17, 18). Leukotrienes and prostaglandins are
involved in a variety of inflammatory diseases, including skin in-
flammation (17, 19). Based on our earlier finding that DHA could
suppress symptoms in AD patients, here we used a mouse model
of AD to assess whether an ointment containing DHA/EPA had
therapeutic effects and also to determine the mechanisms by which
DHA acts (15). Treatment with DHA/EPA alone had no effect on
AD pathology, but treatment with both FK506 and DHA had strong
therapeutic potential in the mouse model of AD. Furthermore, the
effect of DHA/EPA was dependent on inhibition of LTB4 produc-
tion. These data suggest the DHA may suppress symptoms of AD
by inhibiting the production of key inflammatory eicosanoids.
Previous studies have suggested that the effect of FFA on in-
hibiting inflammation is attributable to changes in the fatty acid
composition of cellular phospholipids, since FFAs rather than ara-
chidonic acid can incorporate into cell membranes (20). Because
FFAs are poor substrates for 5- lipoxygenase and cyclooxygenase,
FFA incorporation into cell membranes could in turn suppress the
production of eicosanoid mediators (16). The inhibition of LTB4
production by DHA/EPA treatment in our study also suggested
the inhibitory effect of DHA/EPA on arachidonic acid. Alterna-
tively, DHA and other FFAs could activate the fatty acid receptor
GPR120 on cell surfaces, which may subsequently inhibit phos-
phorylation of the transforming growth factor β -activated kinase 1
(TAK1) that participates in the NF-kB and MAPK signaling path-
ways (21). Given that inhibition of TAK1 by RNAi suppresses Th1
and Th17 differentiation by targeting myeloid cells (22), future
studies on the effect of DHA on TAK1 phosphorylation levels in vivo
would be important to determine if TAK1 is associated with DHA/
EPA-mediated suppression of AD pathology.
Figure 2. DHA/EPA treatment decreases T cell and eosinophil numbers in skin tissue
Dorsal skin tissue from NC/Nga mice treated with DHA/EPA, FK506 or DHA/EPA with FK506 (20 days after initial induction) was digested by
collagenase and dispase. The cell numbers were then counted and the cells were stained with antibodies against CD3, IgM, B220, CD11b, Gr1 or
SiglecF. The number of T cells (CD3+), B cells (IgM+B220+), neutrophils (CD11b+Gr1+), and eosinophils (CD11b+SiglecF+) are expressed as a
total cell number/g of skin tissue. The data are shown as meanS.D. (n=8 in each experiment). **indicates statistical difference (p0.01).The
data are representative of five independent experiments.
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The therapeutic efficacy of DHA/EPA was observed when it
was administered together with FK506 while DHA/EPA alone
failed to ameliorate AD pathology. FK506 is a potent T cell suppres-
sive drug that makes a complex with FKBP resulting in inhibiting
dephosphorylation of NFAT (23). This finding may have two pos-
sible explanations : i) treatment with DHA/EPA alone may be
able to suppress AD, but its effect would be too weak to ameliorate
AD pathology in this AD model ; or ii) Suppression of T cell re-
sponses by FK506 is needed in order for DHA/EPA to exert its
effects in this model. These AD model mice exhibited a scratching
behavior that is related to the progression of AD pathology. FK506
treatment suppressed this scratching behavior (24), and thus this
Figure 3. DHA/EPA treatment decreases IgE and cytokines expression from T cells
(a) AD was induced by painting an ointment containing Dermatophagoides farinae body extract onto the dorsal skin of NC/Nga mice. We painted
FK506 aloneor DHA/EPA with FK506 on the dorsal skin of mice and evaluated serum IgE, IgG1, IgG2, and IgM levels 30 days after initial induction.
The data are shown as meanS.D. (n=8 in each experiment). *indicates statistical difference (p0.05). (b) We applied FK506 alone or DHA with
FK506 on the dorsal skin of mice treated with Biosta. Thirteen days after initial Biosta treatment, CD4+ T cells were purified and stimulated with
plate -coated anti -CD3 mAb for 2 days. Levels of IL-13, IL -17A, IL-22, and IFN-γ in the supernatant were evaluated by ELISA. The data are shown as
meanS.D. (n=8 in each experiment). *indicates statistical difference (p0.05). The data are representative of six independent experiments.
Figure 4. The therapeutic effect of DHA/EPA is attributable to the suppression of LTB4
AD is induced by painting an ointment containing Dermatophagoides farinae body extract onto the dorsal skin of NC/Nga mice. (a) We applied DHA/
EPA or FK506 alone or DHA with FK506 onto the dorsal skin and collected dorsal skin tissue 20 days after initial induction. LTB4 protein levels
were measured by ELISA. The data are shown as meanS.D (n=8 in each experiment). *indicates statistical difference (p0.05). (b) We applied
FK506 alone or DHA/EPA with FK506 onto the dorsal skin and then injected LTB4 at 10 different sites on the dorsal skin (2 pg/site). The clinical
score was evaluated. The data are shown as meanS.D. (n=5 in each experiment). *indicates statistical difference (p0.05).The data are repre-
sentative of three independent experiments.
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compound might be required for DHA/EPA to produce a thera-
peutic effect on AD. In contrast, in AD patients DHA/EPA alone
has treatment efficacy, which might be attributable to the lower
incidence of scratching in humans relative to NC/Nga mice.
In conclusion, DHA/EPA could suppress AD pathology by in-
hibiting LTB4 production in an AD mouse mode. Although the
molecular mechanism by which DHA/EPA suppresses LTB4 in
this AD model awaits further clarification, these data suggest that
ointments including DHA/EPA would be a beneficial treatment for
AD patients when DHA/EPA is administered together with FK 506.
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